CN Patent

CN113754580A — 一种吡啶吗啉类化合物、其制备方法及其应用

Assigned to Shanghai Zawa Pharmaceutical Technology Co ltd · Expires 2021-12-07 · 4y expired

What this patent protects

本发明公开了一种吡啶吗啉类化合物、其制备方法及其应用。本发明提供了一种如式I所示的吡啶吗啉类化合物、其药学上可接受的盐或其药学上可接受的盐的水合物，以上化合物可作为D 2 、D 3 或5‑HT 2A 中的一种或多种的拮抗剂，并用于制备治疗精神分裂症的药物。

USPTO Abstract

本发明公开了一种吡啶吗啉类化合物、其制备方法及其应用。本发明提供了一种如式I所示的吡啶吗啉类化合物、其药学上可接受的盐或其药学上可接受的盐的水合物，以上化合物可作为D 2 、D 3 或5‑HT 2A 中的一种或多种的拮抗剂，并用于制备治疗精神分裂症的药物。

Drugs covered by this patent

tivozanib-hydrochloride (TIVOZANIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN113754580A
Jurisdiction: CN
Classification: —
Expires: 2021-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Zawa Pharmaceutical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.